Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma
Authors:
- Thomas A. BurleyTBThomas A. Burley
- Emma KennedyEKEmma Kennedy
- Georgia BroadGBGeorgia Broad
- Melanie BoydMBMelanie Boyd
- David LiDLDavid Li
- Timothy WooTWTimothy Woo
- Christopher WestCWChristopher West
- Eleni E. LadikouELEleni E. Ladikou
- Iona AshworthIAIona Ashworth
- Christopher FeganCFChristopher Fegan
- Rosalynd JohnstonRJRosalynd Johnston
- Simon MitchellSMSimon Mitchell
Open Access
Abstract
In this study, we evaluated an NF-κB inducing kinase (NIK) inhibitor, CW15337, in primary chronic lymphocytic leukemia (CLL) cells, CLL and multiple myeloma (MM) cell lines and normal B- and T-lymphocytes. Basal NF-κB subunit activity was characterized using an enzyme linked immunosorbent assay (ELISA), and the effects of NIK inhibition were then assessed in terms of cytotoxicity and the expression of nuclear NF-κB subunits following monoculture and co-culture with CD40L-expressing fibroblasts, as a model of the lymphoid niche. CW15337 induced a dose-dependent increase in apoptosis, and nuclear expression of the non-canonical NF-κB subunit, p52, was correlated with sensitivity to CW15337 (p = 0.01; r2 = 0.39). Co-culture on CD40L-expressing cells induced both canonical and non-canonical subunit expression in nuclear extracts, which promoted in vitro resistance against fludarabine and ABT-199 (venetoclax) but not CW15337. Furthermore, the combination of CW15337 with fludarabine or ABT-199 showed cytotoxic synergy. Mechanistically, CW15337 caused the selective inhibition of non-canonical NF-κB subunits and the transcriptional repression of BCL2L1, BCL2A1 and MCL1 gene transcription. Taken together, these data suggest that the NIK inhibitor, CW15337, exerts its effects via suppression of the non-canonical NF-κB signaling pathway, which reverses BCL2 family-mediated resistance in the context of CD40L stimulation.Keywords
Funding Information
- Bloodwise (18005)
- Medical Research Council (MR/V009095/1)
- Sussex Cancer Fund (2018)
- Crawley Leukaemia Research (2018-2021)
- Michael Chowen Research Fund (2018-2021)
This publication has 41 references indexed in Scilit:
- Targeting Nuclear Factor-Kappa B to Overcome Resistance to ChemotherapyFrontiers in Oncology, 2013
- Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationJournal of Experimental Medicine, 2011
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaNature, 2011
- The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood, 2011
- Antigens in chronic lymphocytic leukemia—Implications for cell origin and leukemogenesisSeminars in Cancer Biology, 2010
- Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cellsMolecular Cancer, 2010
- Bone marrow microenvironment and the identification of new targets for myeloma therapyLeukemia, 2008
- Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple MyelomaCancer Cell, 2007
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- A sustained activation of PI3K/NF-κB pathway is critical for the survival of chronic lymphocytic leukemia B cellsLeukemia, 2004